SCHEMBL2919205

SCHEMBL2919205

CCc1cccc2cnc(Cl)nc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.40
GABRA1 P14867 4/20 0.38
GABRB2 P47870 4/20 0.38
PARP1 P09874 1/20 0.35
EGFR P00533 2/20 0.34
TLR8 Q9NR97 1/20 0.34
PIN1 Q13526 1/20 0.34
ELANE P08246 3/20 0.33
KCNH2 Q12809 2/20 0.33
SCN5A Q14524 2/20 0.33
HTR1A P08908 2/20 0.33
TAAR1 Q96RJ0 1/20 0.33
CACNA1C Q13936 1/20 0.33
CYP2C19 P33261 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
DAO P14920 1/20 0.32
DRD2 P14416 1/20 0.32
DRD4 P21917 1/20 0.32
HTR2A P28223 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL856477 0.76 EGFR (0.39) EGFRHTR1ADRD4DRD3
SCHEMBL2917596 0.75 NOS1 (0.39) PARP1EGFRMEN1KMT2A
SCHEMBL28317953 0.74 ELANE (0.37) SYKGABRA1GABRB2ELANEMEN1
SCHEMBL12650507 0.73 EGFR (0.42) GABRA1GABRB2PARP1EGFRTLR8
SCHEMBL12565004 0.72 TERT (0.50) GABRA1GABRB2PARP1TLR8ELANE
SCHEMBL22777313 0.72 KDM4E (0.33) SYKEGFRMEN1KMT2A
SCHEMBL23003201 0.72 EGFR (0.38) PARP1EGFRPIN1MEN1KMT2A
SCHEMBL1634276 0.72 METAP2 (0.48) CYP2C19MEN1KMT2A
SCHEMBL31114211 0.72 BACE1 (0.46) EGFRCYP2C19MEN1KMT2A
SCHEMBL559708 0.72 BACE1 (0.46) EGFRCYP2C19MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed
WO-2009084695-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE DSTYK, ABL1, EEF2K SYK 724/4885GABRA1 1956/4885GABRB2 1906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.